08

08

May

五月

2024

2024

|

|

14:29 PM

14： 下午29点

Europe/Amsterdam

欧洲/阿姆斯特丹

Bayer to unveil late-breaking data from Phase III OASIS 1 and 2 for elinzanetant in the treatment of vasomotor symptoms associated with menopause

拜耳将公布第三阶段OASIS 1和2的晚期数据，用于治疗更年期相关的血管舒缩症状

Not intended for UK Media – The American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting 2024:

不适用于英国媒体–美国妇产科学会2024年年度临床与科学会议：

Summary

摘要

Detailed results from pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and safety of investigational compound elinzanetant will be presented for the first time at this year’s American College of Obstetricians and Gynecology (ACOG) / Elinzanetant is a first dual neurokinin-1,3 (NK-1,3) receptor antagonist being studied for the non-hormonal treatment of moderate to severe VMS associated with menopause, administered orally once daily / Additional presentations include a variety of posters and oral presentations that span across Bayer’s contraception and menopause portfolio as well as two scientific symposia / Presentations demonstrate Bayer’s long-standing commitment in women’s healthcare as the company continues to address relevant unmet medical needs for women.

关键的III期研究OASIS 1和2的详细结果将首次在今年的美国妇产科学院（ACOG）上介绍评估研究化合物依林扎尼坦的疗效和安全性/依林扎尼坦是第一种双重神经激肽-1,3（NK-1,3）受体拮抗剂，正在研究用于与更年期相关的中重度VMS的非激素治疗，每天口服一次/其他演示包括跨越拜耳避孕和更年期组合的各种海报和口头演示，以及两次科学研讨会/演示证明拜耳作为公司在妇女保健方面的长期承诺继续解决妇女未满足的相关医疗需求。

Berlin, May 8, 2024 – Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo, at the upcoming American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting.

柏林，2024年5月8日–拜耳将在即将举行的美国妇产科学会（ACOG）年度临床与科学会议上，介绍关键的III期研究OASIS 1和2的详细结果，评估研究化合物elizanetant与安慰剂的疗效和安全性。

ACOG takes place from May 17 – 19, in San Francisco, CA, United States.Additional presentations will feature new findings from Bayer’s intrauterine systems (IUS) and menopause product portfolio, as well as a scientific symposium session on the science behind menopause symptoms. These presentations demonstrate Bayer’s long-standing commitment to advance women’s healthcare as the company works towards broadening treatment options for women. OASIS 1 and 2 data presentations:Scientific Symposium: OASIS 1 and 2: Elinzanetant Efficacy and Safety Data From 2 Pivotal Studieso   James A.

ACOG于5月17日至19日在美国加利福尼亚州旧金山举行。其他演讲将介绍拜耳宫内系统（IUS）和更年期产品组合的新发现，以及关于更年期症状背后科学的科学研讨会。这些演讲展示了拜耳公司在努力拓宽女性治疗选择的同时，对推进女性医疗保健的长期承诺。OASIS 1和2数据介绍：科学研讨会：OASIS 1和2：来自2项关键研究的Elinzanetant疗效和安全性数据。

Simon, MD and JoAnn V. Pinkerton, MDo   Friday, 17 May, 5:15 – 6:00 PM PST, Location: 154E-Poster #IP05-C: First Phase 3 trial evaluating the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause (OASIS 2)o   JoAnn V. Pinkerton, MDo   Saturday, 18 May, 9:30 – 10:30 AM PST, Location: Hall CE-Poster #IP05-D: Second Phase 3 trial OASIS 1 confirms efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopauseo    James A.

西蒙医学博士和乔安·平克顿医学博士，太平洋标准时间5月17日星期五下午5:15–6:00，地点：154E海报#IP05-C：第一项评估依林扎尼坦治疗更年期相关血管舒缩症状的疗效和安全性的3期临床试验（OASIS 2）o乔安·平克顿医学博士，太平洋标准时间5月18日星期六上午9:30–10:30，地点：霍尔CE海报#IP05-D：第二阶段3试验OASIS 1证实了依林扎尼坦治疗更年期詹姆斯A相关血管舒缩症状的有效性和安全性。

Simon, MDo    Saturday, 18 May, 09:30 – 10:30 AM PST, Location: Hall CAdditional Bayer presentations include:Scientific Symposium: Understanding Menopause: The Science Behind the Symptomso   JoAnn V. Pinkerton, MD, and Victor Navarro, MDo   Saturday, 18 May, 7:00 – 7:45 AM PST, Location: 153E-Poster #IP01-A: LNG-IUS for the Treatment of Endometrial Hyperplasia and Early-stage Endometria.

西蒙，医学博士，星期六，5月18日，上午9:30–10:30，地点：霍尔传统拜耳演讲包括：科学研讨会：了解更年期：症状背后的科学。医学博士JoAnn V.Pinkerton和医学博士Victor Navarro，医学博士，星期六，5月18日，上午7:00–7:45，地点：153E海报#IP01-A：用于治疗子宫内膜增生和早期子宫内膜的LNG-IUS。

Contact for global media inquiries:Katja Wiggers, phone +49 30 221541614Email: katja.wiggers@bayer.comContact for US media inquiries:Courtney Ambrosi, phone 1 (908) 798-1107Email: courtney.ambrosi@bayer.comContact for investor inquiries:Bayer Investor Relations Team, phone +49 214 30-72704Email: ir@bayer.comwww.bayer.com/en/investors/ir-team.

全球媒体咨询联系人：Katja Wiggers，电话+49 30 221541614电子邮件：katja.wiggers@bayer.comContact美国媒体咨询：Courtney Ambrosi，电话1（908）798-1107电子邮件：courtney.ambrosi@bayer.comContact投资者咨询：拜耳投资者关系团队，电话+49 214 30-72704电子邮件：ir@bayer.comwww.bayer.com/en/投资者/ir团队。

Newsroom

新闻编辑室

Downloads

下载

2024-0065e.pdf

2024-0065e.pdf

2024-0065e.rtf

2024-0065e.rtf

Sign up for our Newsletter

注册我们的新闻稿

We will keep you informed about the latest news.

我们将随时向您通报最新消息。

Sign up

注册